We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current AGLE market cap is 48.63M. The company's latest EPS is USD -83.6725 and P/E is -0.35.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 688k | 0 | 0 | 0 | 0 |
| Operating Income | -159.25M | -32.95M | -47.75M | -47.77M | -44.15M |
| Net Income | -217.08M | -40.16M | -63.13M | -43.86M | -38.84M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 18.74M | 2.33M | 886k |
| Operating Income | -80.33M | -81.48M | -65.65M | -84.78M | -258.75M |
| Net Income | -78.25M | -80.89M | -65.8M | -83.82M | -338.79M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 243.53M | 207.27M | 341.86M | 487.6M | 436.07M |
| Total Liabilities | 253.58M | 65.56M | 73.29M | 81.93M | 61.68M |
| Total Equity | -207.37M | -245.4M | 184.02M | 152.27M | 374.39M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 83.18M | 161.62M | 109.93M | 71.14M | 341.86M |
| Total Liabilities | 23.1M | 21.79M | 25.99M | 20.84M | 73.29M |
| Total Equity | 60.08M | 139.83M | 83.94M | 50.31M | 184.02M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -34.28M | -68.87M | -99.91M | -28.54M | -90.79M |
| Investing | 24.51M | -73.12M | -108.39M | -104.96M | -225.48M |
| Financing | 210M | 197.47M | 361.08M | 172.17M | 172.53M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -65.69M | -75.78M | -53.72M | -80.14M | -99.91M |
| Investing | -1.74M | -7.6M | -22.62M | 57.01M | -108.39M |
| Financing | 65.72M | 154.51M | 1.39M | 42.68M | 361.08M |
| Market Cap | 48.63M |
| Price to Earnings Ratio | -0.35 |
| Price to Sales Ratio | 132.5 |
| Price to Cash Ratio | 0.62 |
| Price to Book Ratio | 0.44 |
| Dividend Yield | - |
| Shares Outstanding | 4.05M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | -93.02% |
| 52 Week High | 212.50 |
| 52 Week Low | 2.66 |
| Spread (Intraday) | 2.8 (20%) |
| Company Name | Aeglea BioTherapeutics Inc |
| Address |
1521 concord pike wilmington, delaware 19803 |
| Website | https://www.spyre.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
